Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.
Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR.
Hall AB, et al.
Oncotarget. 2014 Jul 30;5(14):5674-85. doi: 10.18632/oncotarget.2158.
Oncotarget. 2014.
PMID: 25010037
Free PMC article.